For Gilead’s Sofosbuvir, Questions Remain About Breadth Of Indication
Executive Summary
The company seeks a broad label in hepatitis C that would allow for easy integration with other direct-acting antivirals making their way toward FDA approval, but the agency seems to favor an indication limiting use of the first-in-class “nuc” to the ribavirin- and pegylated interferon-containing regimens studied.